BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly to $633 from $565 and keeps an Outperform rating on the shares. The Mounjaro outperformance paired with Novo SELECT data bolster the firm’s outlook for uptake in T2D, the analyst tells investors in a research note. While manufacturing remains constrained, the new RTP site and Trulicity autoinjector synergies with Mounjaro’s injector help Lilly prepare for mounting demand, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY: